An overview of the preapproval information exchange (PIE) from Charlie Dragovich, Senior Director and Client Strategist at Cencora
According to Charlie Dragovich, Senior Director and Client Strategist at Cencora, the PIE Act allows the FDA to grant “an exception to some of their rules and regulations so that manufacturers and payers can feel comfortable pre approval having important discussions about a new product or a new line extension or a new medical device coming to market and preparing it so that it can come to market as quickly as possible.”
Discussions may take place around how many people will use the product and what it will cost.
Dragovich authored a poster titled, ‘Optimizing the timing of pre-approval information exchange (PIE) engagement for oncology products, products for rare diseases, and cell and gene therapies (CGTs),’ which was presented this week at AMCP Nexus 2024, held at the MGM Grand in Las Vegas.
Cencora is a drug wholesale company that partners with pharmaceutical companies and healthcare providers to facilitate care.
With New Drugs in the Offing, Treatment Cost of ATTR-CM Is Projected to Climb | AMCP Nexus 2024
October 16th 2024Several companies are developing new drugs to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), a formerly obscure condition that is getting an increasing amount of attention.
Read More
Health Plans Embrace Biosimilars to Reduce Costs and Improve Patient Access | AMCP Nexus 2024
October 16th 2024How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and patients, according to Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca
Read More
Use of Copay Offset Programs Expected to Rise | AMCP Nexus 2024
October 15th 2024Just a small percentage of employers use alternative funding programs, including accumulators and maximizers. But approximately 60% of employers who do use these programs said in a survey they are effective at managing healthcare costs.
Read More